The Relationship between Sclerostin and Kidney Transplantation Mineral Bone Disorders: A Molecule of Controversies
Calcified Tissue International · 2024
DOI: 10.1007/s00223-024-01261-w ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Calcified Tissue International, 2024. Verfasst von Baris Afsar und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, School of Medicine, Suleyman Demirel University, Isparta, Turkey. afsarbrs@yahoo.com. Hauptthemen laut MEDLINE: Kidney Transplantation, Adaptor Proteins, Signal Transducing. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 113 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Suleyman Demirel University.
Abstract (Originalsprache)
Kidney transplantation is the most effective treatment option for most patients with end-stage kidney disease due to reduced mortality, decreased cardiovascular events and increased quality of life compared to patients treated with dialysis. However, kidney transplantation is not devoid of both acute and chronic complications including mineral bone disorders (MBD) which are already present in patients with chronic kidney disease (CKD) before kidney transplantation. The natural history of MBD after kidney transplantation is variable and new markers are needed to define MBD after kidney transplantation. One of these promising molecules is sclerostin. The main action of sclerostin is to inhibit bone formation and mineralization by blocking osteoblast differentiation and function. In kidney transplant recipients (KTRs), various studies have shown that sclerostin is associated with graft function, bone parameters, vascular calcification, and arterial stiffness although non-uniformly. Furthermore, data for inhibition of sclerostin with monoclonal antibody romosozumab for treatment of osteoporosis is available for general population but not in KTRs which osteoporosis is highly prevalent. In this narrative review, we have summarized the studies investigating the change of sclerostin before and after kidney transplantation, the relationship between sclerostin and laboratory parameters, bone metabolism and vascular calcification in the context of kidney transplantation. We also pointed out the uncertainties, explained the causes of divergent findings and suggest further potential study topics regarding sclerostin in kidney transplantation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nephrology, School of Medicine, Suleyman Demirel University, Isparta, Turkey. afsarbrs@yahoo.com.
- Department of Nephrology, Saint Loui University, Saint Louis University Hospital, Saint Louis, MO, USA. afsarbrs@yahoo.com.
- Department of Nephrology, School of Medicine, Suleyman Demirel University, Isparta, Turkey.
- Department of Nephrology, Saint Loui University, Saint Louis University Hospital, Saint Louis, MO, USA.
ORCID-Profile: Baris Afsar
Förderung
- Suleyman Demirel University
Zitieren
APA
Afsar, B., Afsar, R. E., Caliskan, Y., & Lentine, K. L. (2024). The Relationship between Sclerostin and Kidney Transplantation Mineral Bone Disorders: A Molecule of Controversies. Calcified Tissue International. https://doi.org/10.1007/s00223-024-01261-w
Vancouver
Afsar B, Afsar RE, Caliskan Y, Lentine KL. The Relationship between Sclerostin and Kidney Transplantation Mineral Bone Disorders: A Molecule of Controversies. Calcified Tissue International. 2024. doi:10.1007/s00223-024-01261-w
BibTeX
@article{Afsar2024,
author = {Afsar, Baris and Afsar, Rengin Elsurer and Caliskan, Yasar and Lentine, Krista L},
title = {The Relationship between Sclerostin and Kidney Transplantation Mineral Bone Disorders: A Molecule of Controversies},
journal = {Calcified Tissue International},
year = {2024},
doi = {10.1007/s00223-024-01261-w}
}
EUVIMED